India Authority Clears CIPL Merger With IPC
This article was originally published in PharmAsia News
The proposed merger of Central India Pharmacopoeia Laboratory with Indian Pharmacopoeia Commission won the approval of Indian authorities. The Union Cabinet also approved staff, asset and liability transfers from CIPL to IPC. The approval enables the pre-merger IPC to continue to function in advance of the actual merger with CIPL. (Click here for more
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.